the problem incurred with the CAR T Cells regimen is not that they are ineffective, it is producing them in affordable numbers and having a receptor on off switch to end the therapy.
Very true. Scalability will be a challenge. As for the on-off, there is a company called Bellicum Pharma doing just. The CAR’s turn on only in the presence of a drug (rimiducid) which is injected into the patient. Otherwise they remains off.